Berlin and Freiburg, Germany - November 12, 2025
We are pleased to share that Prior Labs is collaborating with Oxford Cancer Analytics (OXcan) to apply TabPFN to high-clinical-need lung diseases, focusing on more accurate differentiation across complex disease stages.
OXcan is pioneering a liquid-biopsy approach that leverages the proteome to detect patterns of lung disease from blood. By combining advanced proteomic data with TabPFN's ability to efficiently analyse structured biomedical data, this collaboration aims to strengthen diagnostic capabilities to guide better treatment decisions for patients.
Prior Labs and OXcan will collaborate closely to optimize pipeline design, integrate frontier model techniques, and support secure deployment in laboratory environments. Prior Labs' TabPFN represents a production-ready means to move cutting-edge analytics into medical applications. Both collaborators believe that foundation models for tabular data represent a new approach to generating insights from complex biological datasets, thereby enhancing the clinical diagnostic toolset.
"Complex lung diseases are one of the most challenging areas in medicine. This collaboration with Prior Labs and TabPFN enables us to improve our capabilities to deal with the complex datasets generated by OXcan's comprehensive proteome analysis to derive actionable clinical insights."
— Simon Meier, CEO, Oxford Cancer Analytics
"Healthcare is one of the most meaningful domains where advances in foundation models translates to human outcomes. OXcan's work with Prior Labs and proteomic data reflects the next chapter of liquid biopsy for lung disease and is a proof of production-grade applicability of TabPFN within the domain. We are excited to support OXcan’s vision and help bring foundation models into real clinical workflows."
— Sauraj Gambhir, Co-Founder and Managing Director, Prior Labs
"Early and accurate differentiation in lung disease is critical for guiding care and improving patient outcomes. Proteomic signals offer a rich and underutilized signal, and pairing them with tabular foundation models will unlock diagnostic insights that were previously out of reach. We look forward to working closely with OXcan on this important clinical frontier."
— Noah Hollmann, Co-Founder and CTO, Prior Labs
Both parties are excited to advance innovation through this collaboration.
At Prior Labs, we're building Multimodal Tabular Foundation Models (TFMs), starting with TabPFN. While foundation models have transformed text and images, tabular data has remained largely untouched. Founded in Germany, Prior Labs partners with leading enterprises to revolutionize how we approach scientific discovery, medical research, financial modeling, and business intelligence.
Prior Labs is backed by leading institutional investors, including Balderton Capital, XTX Ventures, the Hector Foundation (SAP Founder Hans Werner-Hector), Atlantic Labs, and Galion.exe, alongside top-tier AI and tech leaders.
Oxford Cancer Analytics (OXcan) is an emerging diagnostics company that leverages advanced proteomics and machine learning to create innovative tests for earlier and more accurate assessment of lung diseases. Founded in Oxford, OXcan partners with leading research and clinical institutions to accelerate the translation of laboratory breakthroughs into improved patient care.
For more information, please visit oxcan.org and follow OXcan on LinkedIn.
Media Contacts:
Lilly Wehrhahn (lilly@priorlabs.ai)
Founders Associate, Prior Labs
Rosette Joseph (r.joseph@oxcan.org)
Operations and Communications Manager, Oxford Cancer Analytics
%20(1).svg)
